Developer docs
API playgroundTry for free, no card

Search company profiles

Vuno

Full company profile

uuid0000w6r

Namestring
Vuno
Legal namestring
주식회사 뷰노
Websiteurl
vuno.co
Company typeenum
Private
Founded yearint
2014
Descriptiontext

VUNO Inc. is a Seoul-based, KOSDAQ-listed medical AI company founded in 2014 that develops deep learning-based software for diagnostic decision support and clinical monitoring. The company's core platform analyzes medical imaging (chest X-ray, fundus, CT, MRI), digital pathology slides, biosignals (ECG, vital signs), and speech to deliver AI medical devices marketed under the VUNO Med brand and a consumer health platform under the VUNO Care brand.

The product portfolio comprises four primary offerings: VUNO Med-Chest X-ray (abnormality detection in chest radiographs), VUNO Med-Fundus AI (12-class fundus finding classification), VUNO Med-DeepCARS (24-hour cardiac arrest risk prediction from vital signs, FDA-approved with a validated 21% reduction in cardiac arrest in a secondary hospital study), and VUNO Care-HATIV, a chronic disease management platform that extends clinical monitoring into the consumer health domain via VUNO Mall and Naver Smart Store. VUNO holds FDA approvals for multiple AI medical devices and Korea MFDS clearances, supported by ISO/IEC 27001:2022 and ISO/IEC 27701:2019 certifications.

VUNO monetizes through B2B sales of medical AI software to hospitals and healthcare systems (quote-based annual licensing), B2C subscriptions and unit sales via its consumer health e-commerce storefronts, and international licensing/partnership revenue. Distribution combines direct enterprise sales in Korea with channel partnerships in Europe (Contextflow in Austria, Mesalvo in Germany targeting 900+ hospitals) and a US subsidiary (VUNO Med Inc.) for the American market. Reported Q1 2026 revenue was 61억 won (6.1 billion KRW), with cumulative disclosed funding of approximately $37M across multiple rounds between 2014 and 2026.

Short descriptiontext

VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical AI software, diagnostic imaging AI, cardiac arrest prediction, digital pathology AI, chronic disease platform
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAGAI
Healthcare & Wellness Personalization
NAICS code3 codes
  • Software Publishers5132
  • Custom Computer Programming Services541511
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical AI Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1VUNO Med (Medical Device AI Software)
TypeOne Time License
Description

Sale of FDA-approved and Korea MFDS-cleared AI medical devices (Chest X-ray, Fundus AI, DeepCARS) to hospitals and healthcare systems. Revenue generated from device licensing, software subscriptions, and potentially one-time device sales.

vuno.co:443
2VUNO Care - HATIV (Consumer Health Platform)
TypeSubscription Recurring
Description

Chronic disease management platform sold directly to consumers via e-commerce (VUNO Mall, Naver Smart Store). Subscription or unit-based pricing for personal health monitoring devices and services.

vuno.co:443
3International Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Revenue from international market expansion through licensing agreements, partnerships with European distributors (Contextflow, Mesalvo), and potential royalty arrangements as DeepCARS and other solutions enter new geographies.

morningstar.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1B2B Medical AI Solutions (VUNO Med)
ModelOtherBilling cadenceAnnual
Notes

Quote-based pricing negotiated directly with VUNO sales team. No public pricing page available.

vuno.co:443
2Consumer Health Platform (VUNO Care/HATIV)
ModelSubscriptionBilling cadenceMonthly
Notes

Sold via VUNO Mall and Naver Smart Store e-commerce platforms with product-specific pricing.

vuno.co:443
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 8 records shown
1VUNO Med
Description

Medical AI solutions brand including Chest X-ray, Fundus AI, and DeepCARS products for healthcare professionals

vuno.co:443
+7 more records
Core offering1 text field

VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 21% reduction in cardiac arrest occurrences validated in secondary hospital study
+2 more records
Product overview1 text field

Vuno offers a unified medical AI platform with two main product lines: VUNO Med and VUNO Care. VUNO Med comprises diagnostic AI solutions including Chest X-ray (AI-powered chest X-ray analysis), Fundus AI (fundus image analysis), and DeepCARS (cardiac arrest prediction using vital signs/ECG). VUNO Care includes HATIV, a chronic disease management platform extending clinical healthcare services to personal health monitoring. The platform analyzes diverse medical data including medical imaging (CT/X-ray/MRI), pathology slides, biosignals (ECG/vital signs), and supports speech processing. Vuno Med products are FDA-approved and deployed in hospitals, while the company is expanding globally into US and European markets.

Product and service4 records
1VUNO Med-Chest X-ray
CategoryMedical Imaging AI
Description

AI medical device software that accurately identifies the presence of major abnormal findings in chest X-ray images and pinpoints the suspected location of abnormalities. Sold to hospitals, radiology departments, and healthcare institutions as an FDA-approved and Korea MFDS-cleared AI medical device for clinical decision support.

2VUNO Med-Fundus AI
CategoryMedical Imaging AI
Description

AI medical device software that classifies normal versus abnormal fundus images and detects the presence or absence of 12 common fundus findings. Sold to hospitals, ophthalmology clinics, and healthcare institutions for retinal screening and diagnostic decision support.

3VUNO Med-DeepCARS
CategoryClinical Decision Support AI
Description

FDA-approved AI medical device that predicts the risk of cardiac arrest within 24 hours based on patient vital signs including ECG data. Validated in a secondary hospital study demonstrating a 21% reduction in cardiac arrest occurrences. Sold to hospitals and healthcare systems as an Early Warning System for clinical decision support.

4VUNO Care-HATIV
CategoryConsumer Health Platform
Description

Chronic disease total platform service that extends VUNO's medical AI capabilities from the clinical domain into personal health management, integrating ECG measurement, vital sign monitoring (heart rate, blood pressure, blood glucose, body temperature), and symptom tracking for chronic disease patients. Sold directly to individual consumers via VUNO Mall and Naver Smart Store as a subscription or unit-priced personal health device/service.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Korean Society of Tuberculosis and Respiratory Diseases
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

VUNO signed an MOU with the Korean Society of Tuberculosis and Respiratory Diseases to strengthen clinical evidence for medical AI. The partnership aims to advance clinical validation and scientific evidence for VUNO's AI diagnostic solutions, particularly VUNO Med-Chest X-ray for tuberculosis and respiratory disease detection.

koreabiomed.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

VUNO Inc. signed a strategic MOU with Austrian imaging AI company Contextflow to expand the use of VUNO Med-DeepCARS (AI-based cardiac arrest prediction solution) in Europe. The collaboration involves technical integration, clinical validation, and joint go-to-market activities targeting European hospital markets. Contextflow contributes imaging AI expertise and local market access in Austria and broader Europe.

3Mesalvo (Germany)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

VUNO Inc. signed a strategic MOU with German hospital information system provider Mesalvo to expand DeepCARS in Europe. Mesalvo contributes hospital IT system integration capabilities and reimbursement strategy expertise. The partnership aims to reach over 900 hospitals across Europe through technical integration, validation, and reimbursement strategy collaboration.

morningstar.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-based medical imaging AI company offering AI worklist triage and diagnostic support across CT, X-ray, and MRI — directly comparable to VUNO Med's imaging portfolio for hospital radiology departments.

TypeDirect peer
Description

South Korean medical AI company and the most direct competitor to VUNO, especially in AI chest X-ray (Lunit INSIGHT CXR) and oncology imaging. Closely comparable product set, geography, regulatory profile, and customer base.

TypeDirect peer
Description

Lithuania-based AI company developing chest X-ray and orthopedic imaging AI products, including autonomous reporting — directly comparable to VUNO Med's X-ray AI offering.

TypeDirect peer
Description

US-based medical imaging AI company focused on neurovascular and vascular imaging AI — comparable to VUNO in clinical decision-support imaging AI sold to hospital systems, though in a different clinical vertical.

TypeRegional player
Description

South Korean AI company focused on digital pathology AI for prostate cancer — comparable peer to VUNO in Korean medical AI ecosystem and overlapping digital pathology capability.

6Nanox (Zebra Medical Vision)
TypeBroad incumbent
Description

Global medical imaging company that acquired Zebra Medical Vision — offers AI-driven imaging analytics platform comparable to VUNO Med's imaging portfolio across a broader clinical and hardware-integrated footprint.

TypeDirect peer
Description

Australia-based AI company offering comprehensive chest X-ray abnormality detection (200+ findings) — direct competitor to VUNO Med-Chest X-ray in the AI triage market.

TypeEmerging player
Description

Austrian imaging AI company partnered with VUNO for DeepCARS distribution. Overlaps with VUNO's radiology AI capabilities (CT lung and 3D imaging) and is a meaningful adjacent peer in the EU hospital AI market.

TypeRegional player
Description

South Korean AI healthcare company developing stroke and brain imaging AI — a regional peer to VUNO in the Korean medical AI market and one of the named local players in the same Korea AI healthcare category.

TypeDirect peer
Description

India-headquartered medical imaging AI company competing with VUNO Med-Chest X-ray and VUNO Med-Fundus AI. Direct competitor in chest X-ray triage and head CT/trauma AI, sold globally to hospitals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vuno

Medical AI Softwarevuno.co

VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.

What Vuno does

VUNO Inc. is a Seoul-based, KOSDAQ-listed medical AI company founded in 2014 that develops deep learning-based software for diagnostic decision support and clinical monitoring. The company's core platform analyzes medical imaging (chest X-ray, fundus, CT, MRI), digital pathology slides, biosignals (ECG, vital signs), and speech to deliver AI medical devices marketed under the VUNO Med brand and a consumer health platform under the VUNO Care brand.

The product portfolio comprises four primary offerings: VUNO Med-Chest X-ray (abnormality detection in chest radiographs), VUNO Med-Fundus AI (12-class fundus finding classification), VUNO Med-DeepCARS (24-hour cardiac arrest risk prediction from vital signs, FDA-approved with a validated 21% reduction in cardiac arrest in a secondary hospital study), and VUNO Care-HATIV, a chronic disease management platform that extends clinical monitoring into the consumer health domain via VUNO Mall and Naver Smart Store. VUNO holds FDA approvals for multiple AI medical devices and Korea MFDS clearances, supported by ISO/IEC 27001:2022 and ISO/IEC 27701:2019 certifications.

VUNO monetizes through B2B sales of medical AI software to hospitals and healthcare systems (quote-based annual licensing), B2C subscriptions and unit sales via its consumer health e-commerce storefronts, and international licensing/partnership revenue. Distribution combines direct enterprise sales in Korea with channel partnerships in Europe (Contextflow in Austria, Mesalvo in Germany targeting 900+ hospitals) and a US subsidiary (VUNO Med Inc.) for the American market. Reported Q1 2026 revenue was 61억 won (6.1 billion KRW), with cumulative disclosed funding of approximately $37M across multiple rounds between 2014 and 2026.

Vuno firmographics

Firmographics
Name
Vuno
Legal name
주식회사 뷰노
Website
https://vuno.co
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.
Ownership category
akta.pro rank

Vuno industry classification

Industry
Product category
Medical AI Software
NAICS
Software Publishers (5132), Custom Computer Programming Services (541511), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAGAI
Healthcare & Wellness Personalization

Keywords

  • Medical AI software
  • Diagnostic imaging AI
  • Cardiac arrest prediction
  • Digital pathology AI
  • Chronic disease platform

Where Vuno is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Vuno business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. VUNO Med (Medical Device AI Software): Sale of FDA-approved and Korea MFDS-cleared AI medical devices (Chest X-ray, Fundus AI, DeepCARS) to hospitals and healthcare systems. Revenue generated from device licensing, software subscriptions, and potentially one-time device sales.
  2. VUNO Care - HATIV (Consumer Health Platform): Chronic disease management platform sold directly to consumers via e-commerce (VUNO Mall, Naver Smart Store). Subscription or unit-based pricing for personal health monitoring devices and services.
  3. International Licensing and Partnership Revenue: Revenue from international market expansion through licensing agreements, partnerships with European distributors (Contextflow, Mesalvo), and potential royalty arrangements as DeepCARS and other solutions enter new geographies.

Pricing tiers

ModelBillingPrice
OtherAnnualB2B Medical AI Solutions (VUNO Med)
SubscriptionMonthlyConsumer Health Platform (VUNO Care/HATIV)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Vuno product offering

Product offering

Core offering

VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.

Product overview

Vuno offers a unified medical AI platform with two main product lines: VUNO Med and VUNO Care. VUNO Med comprises diagnostic AI solutions including Chest X-ray (AI-powered chest X-ray analysis), Fundus AI (fundus image analysis), and DeepCARS (cardiac arrest prediction using vital signs/ECG). VUNO Care includes HATIV, a chronic disease management platform extending clinical healthcare services to personal health monitoring. The platform analyzes diverse medical data including medical imaging (CT/X-ray/MRI), pathology slides, biosignals (ECG/vital signs), and supports speech processing. Vuno Med products are FDA-approved and deployed in hospitals, while the company is expanding globally into US and European markets.

Differentiator

Problem solved

Functional benefit

Brands

  • VUNO Med: Medical AI solutions brand including Chest X-ray, Fundus AI, and DeepCARS products for healthcare professionals
  • VUNO Care
  • VUNO Med-Chest X-ray
  • VUNO Med-Fundus AI
  • VUNO Med-DeepCARS
  • VUNO Care-HATIV
  • DeepCARS
  • HATIV

Products and services

  • VUNO Med-Chest X-ray AI medical device software that accurately identifies the presence of major abnormal findings in chest X-ray images and pinpoints the suspected location of abnormalities. Sold to hospitals, radiology departments, and healthcare institutions as an FDA-approved and Korea MFDS-cleared AI medical device for clinical decision support.
  • VUNO Med-Fundus AI AI medical device software that classifies normal versus abnormal fundus images and detects the presence or absence of 12 common fundus findings. Sold to hospitals, ophthalmology clinics, and healthcare institutions for retinal screening and diagnostic decision support.
  • VUNO Med-DeepCARS FDA-approved AI medical device that predicts the risk of cardiac arrest within 24 hours based on patient vital signs including ECG data. Validated in a secondary hospital study demonstrating a 21% reduction in cardiac arrest occurrences. Sold to hospitals and healthcare systems as an Early Warning System for clinical decision support.
  • VUNO Care-HATIV Chronic disease total platform service that extends VUNO's medical AI capabilities from the clinical domain into personal health management, integrating ECG measurement, vital sign monitoring (heart rate, blood pressure, blood glucose, body temperature), and symptom tracking for chronic disease patients. Sold directly to individual consumers via VUNO Mall and Naver Smart Store as a subscription or unit-priced personal health device/service.

Quantifiable outcome

  • 21% reduction in cardiac arrest occurrences validated in secondary hospital study
  • +2 more outcomes

Companies that use Vuno

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Vuno technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Vuno partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Korean Society of Tuberculosis and Respiratory DiseasescoreStrategic or Co-development Partner · 2 February 2026VUNO signed an MOU with the Korean Society of Tuberculosis and Respiratory Diseases to strengthen clinical evidence for medical AI. The partnership aims to advance clinical validation and scientific evidence for VUNO's AI diagnostic solutions, particularly VUNO Med-Chest X-ray for tuberculosis and respiratory disease detection.
  • Contextflow (Austria)coreStrategic or Co-development Partner · 28 October 2025VUNO Inc. signed a strategic MOU with Austrian imaging AI company Contextflow to expand the use of VUNO Med-DeepCARS (AI-based cardiac arrest prediction solution) in Europe. The collaboration involves technical integration, clinical validation, and joint go-to-market activities targeting European hospital markets. Contextflow contributes imaging AI expertise and local market access in Austria and broader Europe.
  • Mesalvo (Germany)coreStrategic or Co-development Partner · 28 October 2025VUNO Inc. signed a strategic MOU with German hospital information system provider Mesalvo to expand DeepCARS in Europe. Mesalvo contributes hospital IT system integration capabilities and reimbursement strategy expertise. The partnership aims to reach over 900 hospitals across Europe through technical integration, validation, and reimbursement strategy collaboration.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Vuno competitors and assessment

Company assessment

Direct peers

  • Aidoc: Israel-based medical imaging AI company offering AI worklist triage and diagnostic support across CT, X-ray, and MRI — directly comparable to VUNO Med's imaging portfolio for hospital radiology departments.
  • Lunit: South Korean medical AI company and the most direct competitor to VUNO, especially in AI chest X-ray (Lunit INSIGHT CXR) and oncology imaging. Closely comparable product set, geography, regulatory profile, and customer base.
  • Oxipit: Lithuania-based AI company developing chest X-ray and orthopedic imaging AI products, including autonomous reporting — directly comparable to VUNO Med's X-ray AI offering.
  • RapidAI: US-based medical imaging AI company focused on neurovascular and vascular imaging AI — comparable to VUNO in clinical decision-support imaging AI sold to hospital systems, though in a different clinical vertical.
  • Annalise.ai: Australia-based AI company offering comprehensive chest X-ray abnormality detection (200+ findings) — direct competitor to VUNO Med-Chest X-ray in the AI triage market.
  • Qure.ai: India-headquartered medical imaging AI company competing with VUNO Med-Chest X-ray and VUNO Med-Fundus AI. Direct competitor in chest X-ray triage and head CT/trauma AI, sold globally to hospitals.

Regional players

  • Deep Bio: South Korean AI company focused on digital pathology AI for prostate cancer — comparable peer to VUNO in Korean medical AI ecosystem and overlapping digital pathology capability.
  • JLK Inspection: South Korean AI healthcare company developing stroke and brain imaging AI — a regional peer to VUNO in the Korean medical AI market and one of the named local players in the same Korea AI healthcare category.

Broad incumbents

  • Nanox (Zebra Medical Vision): Global medical imaging company that acquired Zebra Medical Vision — offers AI-driven imaging analytics platform comparable to VUNO Med's imaging portfolio across a broader clinical and hardware-integrated footprint.

Emerging players

  • Contextflow: Austrian imaging AI company partnered with VUNO for DeepCARS distribution. Overlaps with VUNO's radiology AI capabilities (CT lung and 3D imaging) and is a meaningful adjacent peer in the EU hospital AI market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vuno social profiles

Digital presence

Vuno compliance and trust

Trust signal

Compliance2 records

Vuno financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vuno leadership team

Management profile

Number of profiles

Profiles4 records

Vuno subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vuno funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vuno M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vuno

What does Vuno do?

VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.

Is Vuno a public or private company?

Vuno is a private company. It is classified as public and is currently operating.

When was Vuno founded?

Vuno was founded in 2014. It employs 51 to 100 people.

Where is Vuno based?

Vuno is headquartered in Seoul, South Korea, in the Asia region.

How does Vuno make money?

Three revenue lines are on record. VUNO Med (Medical Device AI Software) is the primary driver. The others are VUNO Care - HATIV (Consumer Health Platform) and international Licensing and Partnership Revenue.

Who are Vuno's main competitors?

Direct peers on record are Aidoc, Lunit, Oxipit, RapidAI, Annalise.ai and Qure.ai. Regional players are Deep Bio and JLK Inspection. Nanox (Zebra Medical Vision) is listed as a broad incumbent. Contextflow is listed as an emerging player.

Does Vuno have an API?

No public API is recorded for Vuno.

What industry is Vuno in?

Vuno's product category is Medical AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate[AI 클로즈업] 뷰노, 매출 87% 책임지는 '딥카스' 3분기 28% 감소…신규 도입·매출 다변화 과제 : 네이트 뉴스Viewno's DeepCARS AI device revenue fell 28% to 50 billion won in Q3, as new hospital adoptions slowed after a 2024 evaluation deferral ended. DeepCARS accounted for 87% of the company's first nine-month revenue, and its evaluation results in Q4 will determine new contracts.Naver[AI 클로즈업] 뷰노, 매출 87% 책임지는 ‘딥카스’ 3분기 28% 감소… 신규 도입·매출 다변화 과제Viewno's DeepCARS AI device revenue fell 28% year-over-year to 50 billion won in Q3, while overall revenue dropped 47.6% to 56.7 billion won. The company expects Q4 evaluation results to drive new hospital contracts, with cash flow improving but losses widening.The future of tradingVuno Defers Rights Offering Schedule After Regulator Requests Amended FilingVuno deferred its 6,300,000-share rights offering timetable after the Financial Supervisory Service requested an amended filing on November 10, 2026. The regulator suspended the registration statement's effectiveness, and pricing, subscription, and payment dates will be reset upon submission of a revised statement.Naver뷰웍스, 3분기 영업익 110억…전년대비 154.8%↑뷰웍스 reported record Q3 revenue of 61.6 billion won and operating profit of 11 billion won, up 154.8% year-over-year. The profit margin rose to 17.8%, and machine vision camera sales grew 89.7% to 18.7 billion won. The company plans to expand new detector lines and digital pathology to support growth.Nate뷰웍스, 3분기 영업이익 110억 원…전년대비 154.8% 증가 : 네이트 뉴스뷰웍스 reported Q3 revenue of 616 billion won and operating profit of 110 billion won, up 154.8% year-over-year. Machine vision revenue rose 89.7% to 187 billion won, and cumulative revenue reached a record 1836 billion won. The company plans to expand new detector lines and digital pathology.Naver루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기]Lunet announced AI biomarker collaboration with Summit Therapeutics for next-gen immunotherapy, lifting its stock 30% to 14,690 won. Viewno, Neurofit, and others also rose, with Viewno awaiting new medical technology evaluation and Neurofit delaying big-pharma commercialization contracts.Nate루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기] : 네이트 뉴스Korean medical AI firms Lunet, Viewno, and Neurofit saw stock gains, with Lunet partnering with Summit Therapeutics on an immunotherapy AI biomarker platform. Viewno awaits evaluation of its DeepCass device, while Neurofit delays commercialization deals with big pharma. The firms aim to expand AI applications in drug development and clinical trials.Naver뷰노, 입원환자 7만여명 대상 대규모 임상설계 국제논문 게재VUNO published its VITAL-MD protocol in JMIR Research Protocols, a multi-center randomized trial of its AI cardiac arrest prediction device. The study will enroll over 70,000 inpatients across four Korean hospitals, with results expected next year. The trial aims to validate AI's impact on patient outcomes in real clinical settings.Naver"고위험" AI 판단, 정확했나?…뷰노, 대규모 검증Viewno published the protocol for VITAL-MD, a multi-center randomized trial of its AI cardiac arrest predictor DeepCARS, in JMIR Research Protocols. The study will enroll about 70,000 hospitalized patients across four Korean hospitals, with results due in 2027. The trial aims to assess whether AI-based interventions improve patient outcomes.Nate뷰노, '딥카스' 다기관 군집 무작위 배정 연구 국제학술지 게재 : 네이트 뉴스Viewno published its VITAL-MD protocol in JMIR Research Protocols, a multi-center randomized cluster trial of its AI cardiac arrest prediction device. The study will enroll about 70,000 hospitalized patients across four Korean hospitals, with results expected in 2027.